The experimental vaccine, which met the main trial goal, was being tested in more than 11,000 people aged 12 years and older.
EU antitrust regulators has accused Indian drugmaker Alchem International of taking part in a pharmaceutical cartel to fix prices of a key ingredient, which could lead to a hefty fine for the company.
To successfully launch rare disease drugs, with their small patient populations and high costs, pharma manufacturers need to get payers involved in discussions as soon as possible to ensure patient access.
Medicines for rare diseases are a leading contributor to all novel drug approvals and launches.
Companies are overcoming challenges to develop and launch rare disease medicines faster, and data shouldn’t be an obstacle.
Ten years after the Ice Bucket Challenge there are few treatment options for ALS, a fatal neurological disease for which there is no cure. A new public-private collaboration is working to change this.